US3064037A - Dialkylaminoalkyl phenoxyphenylalkanoates - Google Patents
Dialkylaminoalkyl phenoxyphenylalkanoates Download PDFInfo
- Publication number
- US3064037A US3064037A US141313A US14131361A US3064037A US 3064037 A US3064037 A US 3064037A US 141313 A US141313 A US 141313A US 14131361 A US14131361 A US 14131361A US 3064037 A US3064037 A US 3064037A
- Authority
- US
- United States
- Prior art keywords
- acid
- hydroxyphenoxy
- iodo
- lower alkyl
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000001412 amines Chemical class 0.000 claims description 4
- -1 phenoxyphenyl Chemical group 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KSZBMSJSJFZGRF-UHFFFAOYSA-N 2-[4-(4-hydroxy-3-propan-2-ylphenoxy)-3,5-diiodophenyl]acetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(CC(O)=O)=CC=2I)I)=C1 KSZBMSJSJFZGRF-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- UOWZUVNAGUAEQC-UHFFFAOYSA-N tiratricol Chemical compound IC1=CC(CC(=O)O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 UOWZUVNAGUAEQC-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PMCWMZXHMYGAEK-UHFFFAOYSA-N 2-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C(C(O)=O)C)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 PMCWMZXHMYGAEK-UHFFFAOYSA-N 0.000 description 1
- KKJBNMLZBHFYAE-UHFFFAOYSA-N 2-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]acetic acid Chemical compound IC1=CC(CC(=O)O)=CC(I)=C1OC1=CC=C(O)C=C1 KKJBNMLZBHFYAE-UHFFFAOYSA-N 0.000 description 1
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 1
- IWPQDTYMEBIDSZ-UHFFFAOYSA-N 3,5-diiodo-4-(4-methoxyphenoxy)benzoic acid Chemical compound C1=CC(OC)=CC=C1OC1=C(I)C=C(C(O)=O)C=C1I IWPQDTYMEBIDSZ-UHFFFAOYSA-N 0.000 description 1
- LPNQFIJWELQLRO-UHFFFAOYSA-N 4-(4-hydroxyphenoxy)-3,5-diiodobenzoic acid Chemical compound IC1=CC(C(=O)O)=CC(I)=C1OC1=CC=C(O)C=C1 LPNQFIJWELQLRO-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/10—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of a carbon skeleton containing rings
Definitions
- R and R are hydrogen, iodo, or lower alkyl
- B is hydrogen or lower alkyl
- 11 is a positive integer from 0 to 3
- x is a positive integer from 2 to 3.
- lower alkyl is intended a straight or branched chain hydrocarbon of from one to six carbon atoms, as for example methyl, ethyl, isopropyl, t-butyl and the like.
- This invention also includes within its scope the pharmaceutically acceptable non-toxic salts of the above defined bases which are formed from non-toxic organic and inorganic acids.
- Such salts are easily prepared by methods known to the art.
- the base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or by treatment of the base with an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, the desired salt thereby separating directly.
- aqueous miscible solvent such as acetone or ethanol
- non-toxic organic salts are those formed with acids such as maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, 'citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic, as well as with the 8-halotheophyllines, for example 8-bromotheophylline.
- inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids.
- the compounds of this invention possess the ability to normalize high lipid levels in the serum and tissue. At the same time however, the calorigenic properties of these compounds are surprisingly low, thereby minimizing cardiac manifestations such as angina which are so prevalent in many of the antihypercholesterolemic agents of this type. This Very favorable cholesterol loweringcalorigenic ratio renders these compounds as valuable therapeutic agents for the safe reduction of abnormally high cholesterol levels in the animal organism.
- compositions such as tablets, capsules, sus pensions and the like may be employed.
- sustained time release compositions 3,fi4,037 Patented Nov. 13, 1962 which provide a substantially uniform dosage over an extended period of time.
- the compounds of this invention may be prepared by treating a compound of the formula:
- the preferred compounds of the present invention are those wherein R is iodo, B and R are hydrogen, n is 3 and x is 2.
- EXAMPLE 2 The following compounds are substituted for the substituted acetic acid in Example 1: 4-( 3-iodo-hydroxy-pl1enoxy)-3,5-diiodobenzoic acid, 4-(4-hydroxyphenoxy) -3,5- diiodobenzoic acid, 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenylbutyric acid and 4-(4-hydroxyphenoxy)-3,5-diiodophenylbutyric acid.
- diethylaminoethyl esters as their hydrochlorides: diethylaminoethyl 4-(3-iodo-4- hydroxyphenoxy)-3,S-diiodobenzoate, diethylaminoethyl 4- (4-hydroxyphenoxy) 3,5 -diiodobenzoate, diethylam-inoethyl 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodopheny1butyrate and diethylaminoethyl 4-(4-hydroxyphenoxy)-3,5- diiodophenylbutyrate.
- EXAMPLE 4 The following compounds are employed as starting materials in place of 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenylacetic acid (Reagent A) and Z-diethylaminochloroethane (Reagent B) in the procedure of Example 1.
- Reagent A (a) 4-(3,5-diiodo-4-hydroxyphenoxy) -3,5-diiodophenylpropionic acid.
- Reagent B (a) 1-dimethylamine-S-chloropfopane. (b) 1-diethylan1ine-3-chloropropane. (c) 1-diethylamine-3-chloropropane. (d) 1-dibutylamine-Z-chloroethane.
- diethylaminoethyl 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenyl acetate hydrochloride is dissolved in Water and the solution rendered alkaline by the addition of aqueous sodium bicarbonate. The oil which forms is collected, dried over anhydrous magnesium sulfate, and dissolved in anhydrous acetone. There is then added 1 g. of maleic acid and the mixture stirred for 30 minutes. The solid which forms is collected by filtration and dried to yield diethylaminoethyl 4-(3-iodo-4hydroxyphenoxy)-3,5-diiodophenyl acetate as the maleate salt.
- i R and R are each a member selected from the group consisting of hydrogen, iodo, and lower alkyl; B is a member selected from the group consisting of hydrogen and lower alkyl; n is a positive integer from 0 to 3 inclusively; x is a positive integer from 2 to 3 inclusively and the pharmaceutically acceptable non-toxic acid addition salts thereof.
- R is lower alkyl and R and B are hydrogen.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
United States Patent Ofifice 3,064,037 DIALKYLAMINOALKYL PHENOXYPHENYL- ALKANOATES James F. Kerwin, Broomall, Pa., assignor to Smith Kline & French Laboratories, Philadelphia, Pa., a corporation of Pennsylvania No Drawing. Filed Sept. 28, 1961, Ser. No. 141,313 8 Claims. (Cl. 260473) This invention relates to novel organic compounds having useful biological properties and more specifically to amino and dialkylaminoalkyl esters of substituted phenoxyphenyl alkanoic acids. In addition to these valuable hypocholesterolemic compounds themselves, this invention also pertains to processes for their preparation.
The compounds embraced herein may be represented by the following structural formula:
/lower alkyl 30- 40112) n-ooo- (CH1) ,-N
I l lower alkyl R I I wherein Each of R and R is hydrogen, iodo, or lower alkyl, B is hydrogen or lower alkyl,
11 is a positive integer from 0 to 3,
x is a positive integer from 2 to 3.
By the term lower alkyl is intended a straight or branched chain hydrocarbon of from one to six carbon atoms, as for example methyl, ethyl, isopropyl, t-butyl and the like.
This invention also includes within its scope the pharmaceutically acceptable non-toxic salts of the above defined bases which are formed from non-toxic organic and inorganic acids. Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or by treatment of the base with an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, the desired salt thereby separating directly. Exemplary of such pharmaceutically acceptable non-toxic organic salts are those formed with acids such as maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, 'citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic, as well as with the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids.
The compounds of this invention possess the ability to normalize high lipid levels in the serum and tissue. At the same time however, the calorigenic properties of these compounds are surprisingly low, thereby minimizing cardiac manifestations such as angina which are so prevalent in many of the antihypercholesterolemic agents of this type. This Very favorable cholesterol loweringcalorigenic ratio renders these compounds as valuable therapeutic agents for the safe reduction of abnormally high cholesterol levels in the animal organism.
The administration of these compounds may be made by any of the usual methods although the preferred route is oral. For actual administration, the usual pharmaceutical compositions such as tablets, capsules, sus pensions and the like may be employed. Also highly useful forms are sustained time release compositions 3,fi4,037 Patented Nov. 13, 1962 which provide a substantially uniform dosage over an extended period of time.
The compounds of this invention may be prepared by treating a compound of the formula:
R Ii II in which R, R, B and n are as above defined with an aminochloroalkane of the formula:
lower alkyl Cl-(OHgh-N lower alkyl wherein x is as above defined.
Generally these reagents represented by II and III are refluxed in an organic solvent such as ethanol, isopropanol, dioxane or the like, the product separating directly upon cooling of the reaction mixtures. This product is in the form of the hydrochloride salt and is converted to the free amine by treatment with aqueous alkali. The free amines so obtained may then be converted to other pharmaceutically acceptable non-toxic salts as herein described.
The preferred compounds of the present invention are those wherein R is iodo, B and R are hydrogen, n is 3 and x is 2.
The following examples will further serve to typify this invention but these examples are not to be construed as limiting the scope of this invention, the scope being defined by the appended claims.
' EXAMPLE 1 A mixture of 3.1 g. of 4-(3-iodo-4-hydroxyphenoxy)- III . 3,5-diiodophenylacetic acid and 0.8 g. of Z-diethylaminochloroethane is refluxed for 4 hours in ml. of anhydrous isopropanol. At the end of this time the solution is cooled and the solid which forms is collected by filtration and recrystallized from ethanol-petroleum ether to yield the diethylaminoethyl ester of 4-(3-iodo-4- hydroxyphenoxy)-3,5-diiodophenylacetic acid as the hydrochloride.
In a similar fashion 4-(4-hydroxyphenoxy)-3,5-diiodophenylacetic acid is employed in the procedure of this example and there is thus obtained the compound diethylaminoethyl 4 (4 hydroxyphenoxy)-3,5-diiodophenyl acetate as the hydrochloride.
EXAMPLE 2 The following compounds are substituted for the substituted acetic acid in Example 1: 4-( 3-iodo-hydroxy-pl1enoxy)-3,5-diiodobenzoic acid, 4-(4-hydroxyphenoxy) -3,5- diiodobenzoic acid, 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenylbutyric acid and 4-(4-hydroxyphenoxy)-3,5-diiodophenylbutyric acid. There are thus obtained from this procedure the corresponding diethylaminoethyl esters as their hydrochlorides: diethylaminoethyl 4-(3-iodo-4- hydroxyphenoxy)-3,S-diiodobenzoate, diethylaminoethyl 4- (4-hydroxyphenoxy) 3,5 -diiodobenzoate, diethylam-inoethyl 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodopheny1butyrate and diethylaminoethyl 4-(4-hydroxyphenoxy)-3,5- diiodophenylbutyrate.
EXAMPLE 4 The following compounds are employed as starting materials in place of 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenylacetic acid (Reagent A) and Z-diethylaminochloroethane (Reagent B) in the procedure of Example 1.
Reagent A (a) 4-(3,5-diiodo-4-hydroxyphenoxy) -3,5-diiodophenylpropionic acid.
(b) 4-(4-methoxyphenoxy)-3,5-diiodobenzoic acid.
() 4-(4-methoxyphenoxy-3,S-diiodophenylpropionic acid.
(d) 4-(3,5-di-t-butyl-4-hydroxyphenoxy)-3,5-diiodophenylpropionic acid.
Reagent B (a) 1-dimethylamine-S-chloropfopane. (b) 1-diethylan1ine-3-chloropropane. (c) 1-diethylamine-3-chloropropane. (d) 1-dibutylamine-Z-chloroethane.
There are thus formed the following compounds as their hydrochloride:
(a) 3-dimethylaminopropyl 4-(3,5-diiodo 4-hydroxyphenoxy)-3,5-diiodophenyl propionate (b) 3-diethylaminopropyl 4-(4-methoxyphenoxy) -3,5-
diiodo benzoate (c) 3-diethylaminopropyl 4-(4-methoxyphenoxy)-3,5- diiodophenyl propionate (d) Z-dibutylaminoethyl 4-(3,5-di-t-butyl-4-hydroxyphenoxy)-3,5-diiodophenyl propionate EXAMPLE 5 The compounds obtained in the above examples are in the form of the hydrochloride salt and are transformed into their free acid and thence to their pharmaceutically acceptable acid addition salts according to the usual methods known to the art of the following being representative.
One gram of diethylaminoethyl 4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenyl acetate hydrochloride is dissolved in Water and the solution rendered alkaline by the addition of aqueous sodium bicarbonate. The oil which forms is collected, dried over anhydrous magnesium sulfate, and dissolved in anhydrous acetone. There is then added 1 g. of maleic acid and the mixture stirred for 30 minutes. The solid which forms is collected by filtration and dried to yield diethylaminoethyl 4-(3-iodo-4hydroxyphenoxy)-3,5-diiodophenyl acetate as the maleate salt.
EXAMPLE 6 The following procedure is representative of the method methoxide.
4 with 3.12. g. of silver sulfate and at the end of this time the resultant silver bromide is removed by filtration. The filtrate is evaporated under reduced pressure to yield di- 2-isopropylmethoxyphenyl) -iodinium sulfate.
To 50 ml. of dry methanol is added 4.3 g. of ethyl 3,5- diiodo-4-hydroxyphenyl acetate, 4.8 g. of di-(2risopropylmethoxyphenyl)-iodonium sulfate and 0.7 g. of sodium The mixture is refluxed for 1 /2 hours and at the end of this time steamed distilled. The residue is then extracted with warm benzene and these extracts washed with water, dried over magnesium sulfate and evaporated under reduced pressure. The residual oil is refluxed for 2 hours with 27 ml. of acetic acid and 85 for preparing the requisite starting materials of this in- V vention.
' Di (2 isopropylmethoxyphenyl) iodonium bromide (10.1 g.) (prepared from Z-isopropylmethoxybenzene according to the procedure described in US. Patent No. 2,839,583) is moistened with ethanol and suspended in 50 ml. of water. The suspension is shaken for 1%. hours ml. of consant-boiling hydriodic acid. The mixture is then filtered through diatomaceous earth and evaporated to dryness under reduced pressure. The material is taken up in hot ethanol and the solid which forms upon cooling and addition of benzene is collected by filtration and dried to yield 4-(3-isopropyl-4-hydroxyphenoxy)-3,5'diiodophenylacetic acid.
This compound is then refluxed with diethylaminoethyl chloride in dry isopropanol according to the procedure of Example 1. There is thus obtained the diethylaminoethyl ester of 4-(3-isopropyl-4-hydroxyphenoxy)-3,5-diiodophenylacetic acid as the hydrochloride.
I claim:
1. A compound selected from the group consisting of amines of the structural formula:
lower alkyl wherein:
i R and R are each a member selected from the group consisting of hydrogen, iodo, and lower alkyl; B is a member selected from the group consisting of hydrogen and lower alkyl; n is a positive integer from 0 to 3 inclusively; x is a positive integer from 2 to 3 inclusively and the pharmaceutically acceptable non-toxic acid addition salts thereof.
2. A compound according to claim 1 wherein R is iodo, R is hydrogen and B is lower alkyl. 3. A compound according to claim 1 wherein R is iodo, R is lower alkyl and B is lower alkyl.
4. A compound according to claim 1 wherein R is lower alkyl and R and B are hydrogen.
5. The diethylaminoethanol ester of 4-(4-hydroxy3- iodophenxoy}-3,5-diiodophenylacetic acid.
6. The diethylaminoethanol ester of 4-(4-hydroxy-3- isopropylphenoxy) -3,5-diiodophenylacetic acid.
7. The hydrochloride acid-addition salt of the base defined by claim 5.
8. The hydrochloride acid-addition salt of the base defined by claim 6.
References Cited in the file of this patent UNITED STATES PATENTS 2,844,621 Bernstein of al. July 22, 1958 2,928,845 Shapiro et al. Mar. 15, 1960 2,970,165 Michel et a1. Jan. 31, 1961
Claims (1)
1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF AMINES OF THE STRUCTURAL FORMULA:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US141313A US3064037A (en) | 1961-09-28 | 1961-09-28 | Dialkylaminoalkyl phenoxyphenylalkanoates |
| GB33921/62A GB999892A (en) | 1961-09-28 | 1962-09-04 | Dialkylaminoalkyl esters of substituted phenoxyphenyl alkanoic acids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US141313A US3064037A (en) | 1961-09-28 | 1961-09-28 | Dialkylaminoalkyl phenoxyphenylalkanoates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3064037A true US3064037A (en) | 1962-11-13 |
Family
ID=22495153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US141313A Expired - Lifetime US3064037A (en) | 1961-09-28 | 1961-09-28 | Dialkylaminoalkyl phenoxyphenylalkanoates |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US3064037A (en) |
| GB (1) | GB999892A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462473A (en) * | 1967-03-06 | 1969-08-19 | Upjohn Co | Phenoxyphenyl alkanesulfonates |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2844621A (en) * | 1955-11-01 | 1958-07-22 | Olin Mathieson | Alkylaminoalkyl 4-alkoxy-2, 6-dialkylbenzoates |
| US2928845A (en) * | 1958-04-09 | 1960-03-15 | Us Vitamin Pharm Corp | Dialkylaminoalkoxyphenylethanol esters |
| US2970165A (en) * | 1957-10-01 | 1961-01-31 | Warner Lambert Pharmaceutical | Sulfate compounds |
-
1961
- 1961-09-28 US US141313A patent/US3064037A/en not_active Expired - Lifetime
-
1962
- 1962-09-04 GB GB33921/62A patent/GB999892A/en not_active Expired
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2844621A (en) * | 1955-11-01 | 1958-07-22 | Olin Mathieson | Alkylaminoalkyl 4-alkoxy-2, 6-dialkylbenzoates |
| US2970165A (en) * | 1957-10-01 | 1961-01-31 | Warner Lambert Pharmaceutical | Sulfate compounds |
| US2928845A (en) * | 1958-04-09 | 1960-03-15 | Us Vitamin Pharm Corp | Dialkylaminoalkoxyphenylethanol esters |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462473A (en) * | 1967-03-06 | 1969-08-19 | Upjohn Co | Phenoxyphenyl alkanesulfonates |
Also Published As
| Publication number | Publication date |
|---|---|
| GB999892A (en) | 1965-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH02138262A (en) | Novel pharmaceutical activity 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline derivative | |
| US2921070A (en) | Basic esters of 3-methylflavone-8-carboxylic acid | |
| IL24007A (en) | Substituted benzimidazoles | |
| DE69105786T2 (en) | Urea derivatives, their preparation and pharmaceutical compositions containing them. | |
| US4109088A (en) | 2-(indenyloxymethyl) morpholine derivatives | |
| US3064037A (en) | Dialkylaminoalkyl phenoxyphenylalkanoates | |
| CH619935A5 (en) | ||
| FR2625678A1 (en) | Anorexigenic agents based on N-(3-quinuclidinyl)benzamides or -thiobenzamides | |
| US3043842A (en) | Substituted acridans | |
| US3000885A (en) | 2-acyl-10-oxyalkylpiperidinoalkylphenothiazines and process | |
| CH642348A5 (en) | ALKYLTHIOPHENOXYALKYLAMINE. | |
| GB2157684A (en) | Triazolopyrimidines their preparation and use in medicine | |
| FR2634207A1 (en) | [(4-Piperidyl)methyl]benzazepine derivatives, their preparation and their application in therapeutics | |
| US3017427A (en) | 4-amino-2-sulfamylbenzoic acid esters | |
| CH622777A5 (en) | ||
| EP0187509A2 (en) | 9-Aminoalkylfluorenes | |
| DD150060A5 (en) | PROCESS FOR THE PREPARATION OF NEW PHENTHIAZINE DERIVATIVES | |
| US3322783A (en) | Substituted 2-(5-nitro-2-thienyl)-benzimidazoles | |
| US2490834A (en) | Benzhydryl beta hydroxy alkyl amines | |
| US3629289A (en) | Chromanamines | |
| CA1125762A (en) | Dihydronicotinic acid derivatives and process for the preparation thereof | |
| US3917679A (en) | Quaternary ammonium salts of N-dialkylaminoalkyl-N-(2-indanyl)anilines | |
| US3314948A (en) | Heterocyclic compounds | |
| US2890219A (en) | Chjohichinohichio-co- | |
| US3385852A (en) | Alpha-substituted 1-naphthylacetic acids |